Zanubrutinib Demonstrates Superior Progression-Free Survival Versus Ibrutinib For Relapsed/Refractory CLL/SLL: ALPINE Final Analysis

Emmanuelle Ferrant,¹ Jennifer R. Brown,² Barbara Eichhorst,³ Peter Hillmen,⁴ Nicole Lamanna,⁵ Susan M. O'Brien,⁶ Constantine S. Tam,^{7,8} Lugui Qiu,⁹ Maciej Kaźmierczak,¹⁰ Wojciech Jurczak,¹¹ Keshu Zhou,¹² Martin Šimkovič,^{13,14} Jiří Mayer,¹⁵ Amanda Gillespie-Twardy,¹⁶ Alessandra Ferrajoli,¹⁷ Peter S. Ganly,¹⁸ Robert Weinkove,^{19,20} Sebastian Grosicki,²¹ Andrzej Mital,²² Tadeusz Robak,²³ Anders Österborg,^{24,25} Habte A. Yimer,²⁶ Tommi Salmi,²⁷ Megan (Der Yu) Wang,²⁷ Lina Fu,²⁷ Jessica Li,²⁷ Kenneth Wu,²⁷ Aileen Cohen,²⁷ and Mazyar Shadman^{28,29}

¹Département Hématologie, CHU de Lyon-Sud, France ; ²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ³Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany; ⁴St James's University Hospital, Leeds, United Kingdom; ⁵Herbert Inving Comprehensive Cancer Center, Columbia University, New York, NY, USA; ⁶Chao Family Comprehensive Cancer Center, University of California, Invine, CA, USA; ⁷The Alfred Hospital, Melbourne, Victoria, Australia; ⁸Monash University, Melbourne, Victoria, Australia; ⁹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland; ¹¹Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland; ¹²Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; ¹³4th Department of Internal Medicine - Hematology, Masaryk University Hospital, Hradec Kralove, Czech Republic; ¹⁴Faculty of Medicine, Charles University, Prague, Czech Republic; ¹⁵Department of Internal Medicine-Hematology and Oncology, Masaryk University Hospital, Bron, Czech Republic; ¹⁶Faculty of Medicine, Charles University, Allows, VA, USA; ¹⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹⁶Department of Haematology, Christchurch, New Zealand; ¹⁹Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland; ²⁴Department of Hematology, Medical University of Gdańsk, Gdańsk, Poland; ²³Medical University of Lodz, Lodz, Poland; ²⁴Department of Oncology-Pathology, Karolinska Institute of Medical Research, Wellington, New Zealand; ²¹Department of Hematology and Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland; ²²Department of H


Presented at the 34th French Society of Hematology Congress, March 29-30, 2023. **Session SCO 08: SCO 08 - Lymphoproliferative syndromes.**

Disclosures

Emmanuelle Ferrant, MD reports consulting role with and travel expenses from Abbvie, AstraZeneca, and Janssen-Cilag

Bruton Tyrosine Kinase Inhibition in CLL

- B-cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation in CLL and B-cell lymphomas¹
 - BCR signaling is dependent on Bruton's Tyrosine Kinase (BTK)
- Ibrutinib, a first-generation BTK inhibitor, transformed CLL therapy; however, it has properties that limit use²
 - Treatment discontinuation from toxicities has been reported in 16%-23% of patients³⁻⁶
 - Exposure coverage between dosing intervals falls below IC₅₀ and variable BTK occupancy at trough has been observed



Ibrutinib concentration-time profile

¹Singh SP, Dammeijer F and Hendriks RW. *Molecular Cancer.* 2018; 17:57. ²Molis S, Matures E, Tam C, Polliack A. *Hematol Oncol.* 2020; 38: 129-136. ³Sharman JP, Black-Shinn JL, Clark J, et al. *Blood.* 2017;130(suppl 1):4060. ⁴Mato AR, Nabhan C, Thompson MC, et al. *Haematologica.* 2018;103(5):874-879. ⁵Munir T, Brown JR, O'Brien S, et al. *Am J Hematol.* 2019;94(12):1353-1363. ⁶Ghia P, Owen C, Robak T, et al. EHA Abstract EP636 2021.

Differentiating Features of Zanubrutinib

- Zanubrutinib is a second-generation BTK inhibitor
 - Zanubrutinib was designed to have greater BTK specificity than ibrutinib¹
 - Zanubrutinib has exposure coverage above its IC₅₀²
 - Higher drug-concentration/IC₅₀ ratios would be expected to lead to more sustained and complete BTK inhibition to improve efficacy²
- Zanubrutinib has demonstrated superior PFS by IRC over chemoimmunotherapy in treatment-naive CLL/SLL patients without del(17p)³






Figure modified from Ou YC, Tang Z, Novotny W, et al. *Leukemia* & *Lymphoma.* 2021; 62(11):2612-2624.

ALPINE Study Design



Primary Endpoint: ORR (PR+CR) noninferiority and superiority (by investigator)
Key Secondary Endpoints: PFS and incidence of atrial fibrillation
Other Secondary Endpoints: DoR, OS, time to treatment failure, PR-L or higher, PROs, and safety

Patient Disposition




Balanced Demographics and Disease Characteristics

	Zanubrutinib (n=327)	lbrutinib (n=325)
Age, median (range)	67 (35-90)	68 (35-89)
≥65 years, n (%)	201 (61.5)	200 (61.5)
Male, n (%)	213 (65.1)	232 (71.4)
ECOG PS ≥1, n (%)	198 (60.6)	203 (62.5)
Prior lines of systemic therapy, median (range)	1 (1-6)	1 (1-12)
>3 prior lines, n (%)	24 (7.3)	30 (9.2)
del(17p) and/or <i>TP53</i> ^{mut} , n (%)	75 (22.9)	75 (23.1)
del(17p)	45 (13.8)	50 (15.4)
<i>TP53</i> ^{mut} without del(17p)	30 (9.2)	25 (7.7)
del(11q), n (%)	91 (27.8)	88 (27.1)
IGHV mutational status, n (%)		
Mutated	79 (24.2)	70 (21.5)
Unmutated	239 (73.1)	239 (73.5)
Complex karyotype ^a	56 (17.1)	70 (21.5)
Bulky disease (≥5 cm), n (%)	145 (44.3)	149 (45.8)

Zanubrutinib PFS Significantly Superior to Ibrutinib

Median study follow-up of 29.6 months




Data cutoff: 8 Aug 2022.

PFS data assessed by IRC.

Brown JR, Eichhorst E, Hillmen P, et al. N Engl J Med. 2023;388(4):319-332.

Zanubrutinib Improved PFS in Patients with del(17p)/TP53^{mut}




PFS Favored Zanubrutinib Across Subgroups

Subgroup	Zanubrutinil			Ratio (95% CI)ª
	Events/Patients		ITT: 0.65	
Age group				
<65 years	23/126	43/125	H ● →	0 42 (0.25, 0.70)
≥65 years	65/201	77/200		0.78 (0.56, 1.09)
Sex				
Male	59/213	91/232	H • -1	0.61 (0.44, 0.84)
Female	29/114	29/93		0.72 (0.43, 1.21)
Prior lines of therapy				
1–3	80/303	102/295	H i	0.67 (0.50, 0.90)
>3	8/24	18/30	⊢●	0.45 (0.19, 1.04)
Baseline <i>del</i> (17p)/ <i>TP53</i> mutation status				
Present	23/75	34/75		0.52 (0.30, 0.88)
Absent	65/251	86/250	⊢● −1	0.67 (0.49, 0.93)
Baseline IGHV mutation status				
Unmutated	72/239	98/239	H İ H	0.64 (0.47, 0.87)
Mutated	15/79	18/70		0.63 (0.32, 1.26)
Complex karyotype				
Yes	20/56	24/70		0.91 (0.50, 1.66)
No	37/153	45/130	⊢ ●−−1	0.58 (0.37, 0.90)
0.1 0.50 1.00 1.50 2.00				
Favors Zanubrutinib Favors Ibrutinib				


Data cutoff: 8 Aug 2022. ^aHazard ratio and 95% CI were unstratified for subgroups. Brown JR, Eichhorst E, Hillmen P, et al. *N Engl J Med*. 2023;388(4):319-332.

Sensitivity Analyses Are Consistent with Primary PFS Analysis, Including Drug Interruptions and Treatment Discontinuation


Drug Interruptions^{1,2}



Treatment Discontinuation²



Zanubrutinib Showed Higher ORR Assessed by IRC



Data cutoff: 8 Aug 2022.


CR, complete response; CRi, complete response with incomplete bone marrow recovery; nPR, nodular partial response; PR, partial response; PR-L, partial response with lymphocytosis; SD, stable response; PD, progressive disease; NA, not assessed; DC, discontinued prior to first assessment; NE, not evaluable.

Overall Safety/Tolerability Summary

Zanubrutinib safety profile was favorable to ibrutinib

	Zanubrutinib (n=324)	lbrutinib (n=324)			
Median treatment duration, months	28.4	24.3			
Any grade adverse event	318 (98.1)	321 (99.1)			
Grade 3 to 5	218 (67.3)	228 (70.4)			
Grade 5	33 (10.2)	36 (11.1)			
Serious adverse event	136 (42.0)	162 (50.0)			
Adverse events leading to					
Dose reduction	40 (12.3)	55 (17.0)			
Dose interruption	162 (50.0)	184 (56.8)			
Treatment discontinuation	50 (15.4)	72 (22.2)			

Most Common Adverse Events^a



^aAdverse events occurring in ≥15% of patients in either arm. ^bPooled terms.

Brown JR, Eichhorst E, Hillmen P, et al. N Engl J Med. 2023;388(4):319-332.

Zanubrutinib Had A Favorable Cardiac Profile


Lower rate of cardiac events, serious cardiac events, treatment discontinuation, and deaths

- Lower rate of serious cardiac adverse events reported with zanubrutinib
 - A fib/flutter (n=2)
 - MI/ACS (n=2)
 - CHF (n=2)
- Fatal cardiac events:
 - Zanubrutinib, n=0 (0%)
 - Ibrutinib, n=6 (1.9%)

deaths	Zanubrutinib (n=324)	lbrutinib (n=324)
Cardiac adverse events	69 (21.3%)	96 (29.6%)
Serious cardiac adverse events	6 (1.9%)	25 (7.7%)
Cardiac adverse events leading to treatment discontinuation	1 (0.3)	14 (4.3)
Ventricular extrasystoles	1 (0.3)	0
Atrial fibrillation	0	5 (1.5)
Cardiac arrest	0	2 (0.6) ^a
Cardiac failure	0	2 (0.6)
Cardiac failure acute	0	1 (0.3) ^a
Congestive cardiomyopathy	0	1 (0.3) ^a
Myocardial infarction	0	1 (0.3) ^a
Palpitations	0	1 (0.3)
Ventricular fibrillation	0	1 (0.3)

^aCardiac deaths. One death not listed due to myocardial infarction with ibrutinib discontinuation due to diarrhea 14 days prior to the fatal event.

Fewer Atrial Fibrillation/Flutter Events With Zanubrutinib



Conclusions

- Zanubrutinib demonstrated superior PFS over ibrutinib in patients with relapsed/refractory CLL/SLL
 - PFS benefit seen across all major subgroups, including the del(17p)/TP53^{mut} population
- Zanubrutinib has a favorable safety profile compared with ibrutinib
 - Lower rate of grade ≥3 and serious AEs, fewer AEs leading to treatment discontinuation and dose reduction
 - Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fatal cardiac events
- ALPINE is the first study to demonstrate PFS superiority in a head-to-head comparison of BTK inhibitors in patients with relapsed/refractory CLL/SLL;
 zanubrutinib has now proven superiority to ibrutinib in both PFS and ORR

Acknowledgements

- The authors would like to thank our independent data monitoring committee members for their efforts in this study
- Additionally, we would like to thank the BeiGene ALPINE study team for all their efforts and hard work
- Under the direction of the authors, medical writing and editorial support was provided by Regina Switzer, PhD and Elizabeth Hermans, PhD. Logistical support, funded by BeiGene, was provided by Bio Connections LLC
- Previously presented at the 2022 American Society of Hematology (ASH) Annual Meeting

Corresponding Author:

Emmanuelle Ferrant, MD, e-mail: emmanuelle.ferrant2@chu-lyon.fr